September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
OCTA in atrophic maculopathies
Author Affiliations & Notes
  • Giovanni Staurenghi
    University of Milan, Milano, Italy
  • Footnotes
    Commercial Relationships   Giovanni Staurenghi, Alcon (C), Allergan (C), Bayer (C), Genentech (C), Heidelberg Engineering (C), Nidek (F), Novartis (C), Optovue (F), Roche (C), Zeiss Meditec (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Giovanni Staurenghi; OCTA in atrophic maculopathies. Invest. Ophthalmol. Vis. Sci. 2016;57(12):No Pagination Specified.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : Previous published studies with Indocyanine Green Angiography hypothesize the lack of choriocapillaries as a differences between macular atrophy secondary to age-related macular degeneration and Stargardt's disease (Giani A. et al. Invest Ophthalmol Vis Sci. 2012 Jun 26;53(7):3999-4004). These is confirmed by the analysis of macular atrophy by OCTA. In STGD patients OCTA revealed an extensive loss of choriocapillaris in the central area with persisting tissue at the margin of RPE atrophy; In GA population the central part of atrophy of the RPE is characterized by persistency of Sattler layer and rarefied choriocapillary

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.